$1.8 Billion is the total value of Alphabet Inc.'s 58 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 7.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PATH | UiPath Inccl a | $247,045,915 | +38.2% | 14,068,674 | 0.0% | 13.70% | +31.9% | |
| Prime Medicine, Inc. | $163,401,662 | -33.8% | 13,284,688 | 0.0% | 9.06% | -36.8% | ||
| CRWD | Buy | Crowdstrike Hldgs Inccl a | $159,707,226 | +143.8% | 1,163,538 | +87.0% | 8.86% | +132.8% |
| OSCR | Oscar Health Inc. | $157,240,332 | +165.9% | 24,042,864 | 0.0% | 8.72% | +153.8% | |
| VERV | Verve Therapeutics Inc. | $152,117,820 | -25.5% | 10,549,086 | 0.0% | 8.44% | -28.8% | |
| DXCM | Dexcom Inc | $145,225,000 | +2.6% | 1,250,000 | 0.0% | 8.05% | -2.0% | |
| Planet Labs PBC | $125,534,579 | -9.7% | 31,942,641 | 0.0% | 6.96% | -13.7% | ||
| EQRX Inc. | $92,490,424 | -21.1% | 47,675,476 | 0.0% | 5.13% | -24.7% | ||
| SNOW | Snowflake Inccl a | $82,638,341 | +7.5% | 535,604 | 0.0% | 4.58% | +2.6% | |
| Sell | Duolingo Inc. | $74,692,064 | +49.1% | 523,824 | -25.6% | 4.14% | +42.3% | |
| Buy | Gitlab Inc. | $66,307,739 | +12.7% | 1,933,734 | +49.4% | 3.68% | +7.6% | |
| Freshworks Inc | $61,986,739 | +4.4% | 4,035,595 | 0.0% | 3.44% | -0.3% | ||
| Robinhood Mkts Inc | $47,856,075 | +19.3% | 4,928,535 | 0.0% | 2.65% | +13.9% | ||
| LYFT | Sell | Lyft Inc | $34,318,041 | -40.8% | 3,702,054 | -29.6% | 1.90% | -43.4% |
| RLAY | Relay Therapeutics Inc. | $25,837,362 | +10.2% | 1,568,753 | 0.0% | 1.43% | +5.3% | |
| DM | Desktop Metal Inc. | $25,412,079 | +69.1% | 11,048,730 | 0.0% | 1.41% | +61.4% | |
| Benson Hill Inc. | $17,655,112 | -55.5% | 15,352,271 | 0.0% | 0.98% | -57.5% | ||
| ME | 23andMe Holding Co. | $15,359,870 | +5.6% | 6,736,785 | 0.0% | 0.85% | +0.8% | |
| LYEL | Lyell Immunopharma Inc. | $13,841,695 | -32.0% | 5,865,125 | 0.0% | 0.77% | -35.0% | |
| ILMN | Illumina Inc. | $12,434,449 | +15.0% | 53,470 | 0.0% | 0.69% | +9.7% | |
| GLUE | Monte Rosa Therapeutics Inc. | $11,404,677 | +2.4% | 1,464,015 | 0.0% | 0.63% | -2.3% | |
| RAPT | RAPT Therapeutics Inc. | $9,913,955 | -7.3% | 540,270 | 0.0% | 0.55% | -11.4% | |
| BEAM | Beam Therapeutics Inc. | $9,847,514 | -21.7% | 321,604 | 0.0% | 0.55% | -25.3% | |
| SANA | Sana Biotechnology Inc. | $9,196,875 | -17.2% | 2,812,500 | 0.0% | 0.51% | -20.9% | |
| Invivyd Inc. | $6,816,942 | -20.0% | 5,680,785 | 0.0% | 0.38% | -23.6% | ||
| DBTX | Decibel Therapeutics Inc. | $4,941,499 | +47.3% | 1,636,258 | 0.0% | 0.27% | +40.5% | |
| VACC | Vaccitech PLCads | $3,390,563 | -4.7% | 1,513,644 | 0.0% | 0.19% | -9.2% | |
| FHTX | Foghorn Therapeutics Inc. | $3,105,586 | -2.8% | 500,901 | 0.0% | 0.17% | -7.5% | |
| MGTA | Magenta Therapeutics Inc. | $2,637,919 | +97.5% | 3,339,138 | 0.0% | 0.15% | +87.2% | |
| Tenaya Therapeutics Inc. | $2,609,759 | +41.8% | 915,705 | 0.0% | 0.14% | +35.5% | ||
| VERA | Vera Therapeutics Inc.cl a | $2,340,261 | -59.9% | 301,580 | 0.0% | 0.13% | -61.7% | |
| Sell | Rani Therapeutics Hldgs Inc. | $2,314,219 | -23.1% | 448,492 | -12.1% | 0.13% | -26.9% | |
| Tscan Therapeutics Inc. | $2,261,868 | +37.3% | 1,077,080 | 0.0% | 0.12% | +30.2% | ||
| KRON | Kronos Bio Inc. | $2,099,819 | -9.9% | 1,438,232 | 0.0% | 0.12% | -14.1% | |
| EXAS | Exact Sciences Corp | $1,573,531 | +37.0% | 23,205 | 0.0% | 0.09% | +29.9% | |
| SPRO | Spero Therapeutics Inc. | $1,290,470 | -16.2% | 889,979 | 0.0% | 0.07% | -19.1% | |
| Hyperfine Inc. | $1,294,157 | +71.4% | 898,720 | 0.0% | 0.07% | +63.6% | ||
| AUTL | Autolus Therapeutics PLCspon adr | $1,284,802 | -3.2% | 698,262 | 0.0% | 0.07% | -7.8% | |
| ALEC | Alector Inc. | $1,088,611 | -32.9% | 175,866 | 0.0% | 0.06% | -36.2% | |
| Science 37 Holdings Inc. | $898,033 | -33.3% | 3,207,260 | 0.0% | 0.05% | -35.9% | ||
| TSHA | Taysha Gene Therapies Inc. | $512,706 | -64.6% | 640,882 | 0.0% | 0.03% | -66.7% | |
| OPRT | Oportun Finl Corp | $365,882 | -29.9% | 94,788 | 0.0% | 0.02% | -33.3% | |
| NVTA | Buy | Invitae Corp | $318,068 | -20.8% | 235,606 | +9.1% | 0.02% | -21.7% |
| CRTX | Quince Therapeutics Inc | $295,030 | +143.7% | 189,122 | 0.0% | 0.02% | +128.6% | |
| New | Mondee Holdings Inc. | $205,567 | – | 18,420 | +100.0% | 0.01% | – | |
| EVLO | Evelo Biosciences Inc. | $190,889 | -88.8% | 1,060,495 | 0.0% | 0.01% | -88.9% | |
| RGEN | Repligen Corp | $64,482 | -0.6% | 383 | 0.0% | 0.00% | 0.0% | |
| Cue Health Inc | $49,140 | -12.1% | 27,000 | 0.0% | 0.00% | 0.0% | ||
| FULC | Sell | Fulcrum Therapeutics Inc | $40,647 | -97.8% | 14,262 | -94.4% | 0.00% | -98.1% |
| Exit | Velo3d Inc | $0 | – | -572,400 | -100.0% | -0.06% | – | |
| Exit | Amplitude Inc | $0 | – | -189,447 | -100.0% | -0.13% | – | |
| NEWR | Exit | New Relic Inc. | $0 | – | -91,132 | -100.0% | -0.30% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPERO THERAPEUTICS INC | 24 | Q3 2023 | 3.5% |
| AUTOLUS THERAPEUTICS PLC | 22 | Q3 2023 | 2.8% |
| Magenta Therapeutics Inc. | 21 | Q2 2023 | 3.8% |
| DEXCOM INC | 20 | Q3 2023 | 17.4% |
| Evelo Biosciences Inc. | 20 | Q1 2023 | 1.6% |
| ALECTOR INC | 19 | Q3 2023 | 1.1% |
| Lyft Inc | 18 | Q2 2023 | 51.9% |
| QUINCE THERAPEUTICS INC | 18 | Q3 2023 | 0.6% |
| Arcus Biosciences Inc | 17 | Q1 2022 | 12.7% |
| FULCRUM THERAPEUTICS INC | 17 | Q3 2023 | 0.7% |
View Alphabet Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ARRIS International plc | February 14, 2019 | 7,603,500 | 4.4% |
View Alphabet Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K | 2024-04-25 |
| 144 | 2024-04-17 |
| 144 | 2024-04-17 |
| 4 | 2024-04-17 |
| 4 | 2024-04-15 |
| 144 | 2024-04-12 |
| 4 | 2024-04-04 |
| 144 | 2024-04-03 |
| 144 | 2024-04-03 |
| 4 | 2024-04-02 |
View Alphabet Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.